FDA
-
-
-
-
-
-
-
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
-
-
-
-
-
-
-
William Blair: 'we view BridgeBio as a core smidcap biotech holding'
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $89 at Raymond James
-
-
-
-
-
-
-
BridgeBio's acoramidis shows mortality benefit in ATTR-CM variant patients
-
-
-
-
-
-
-
BridgeBio reports positive phase 3 trial results for LGMD2I/R9 drug
-
-
-
-
-
-
-
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

